


INDIA BIOTECH HANDBOOK 2026



Association of Biotechnology Led Enterprises

able

Pursuing
Infinite
Opportunities

Association of Biotechnology Led Enterprises



Association of Biotechnology Led Enterprises - ABLE is a not-for-profit pan-India forum that represents the Indian Biotechnology Sector. It was launched in April 2003, after industry leaders felt a need to form an exclusive forum to represent the Indian Biotechnology Sector.

ABLE has over 400 members from all across India representing all verticals of the sector like Agribiotech, Bio-pharma, Industrial biotech, Bioinformatics, Investment banks and Venture Capital firms, leading Research and Academic Institutes and Law Firms and Equipment Suppliers.

The primary focus of ABLE is to accelerate the pace of growth of the Biotechnology sector in India, through partnering with the Government in

their biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaboration and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector.

ABLE Council of Presidents, that comprises of all past presidents of the organization, has been set up to provide impetus to the growth of the Biotech business ecosystem to leverage their multi-sectoral expertise. ABLE thus catalyses a symbiotic interface between the industry, the government, academic and research institutes and domestic and international investors.

 www.ableindia.in

 info@ableindia.org.in

Pursuing Infinite Opportunities!

Table of Contents

Table of Contents

Foreword by President	4
India's BioEconomy at a Glance	6
India's BioEconomy Outlook to 2035	10
India Delegation @ BIO 2026	16
India Pavilion at BIO 2026	22
Program Schedule	26
India Pavilion Exhibitors	28

Acknowledgements

The India Biotech Handbook has been envisioned and published by **Ms. Indrila Sengupta**, Manager - Technical Services, Association of Biotechnology Led Enterprises (ABLE). The content development, compilation, and analysis were coordinated and carried out under her leadership with support from the ABLE team.

The advertisements and partnership coordination were managed by **Ms. Pavana Praveen**, Manager - Operations, ABLE.

Mr. Narayanan Suresh served as Advisor to the India Biotech Handbook, providing strategic guidance and industry insights for the publication.

Dr. Balasubramanya S., General Manager, Association of Biotechnology Led Enterprises (ABLE), served as the Chief Coordinator for the INDIA Pavilion initiatives and overall stakeholder coordination associated with the publication.

Comments and questions are welcome and should be addressed to:

info@ableindia.org.in

ASSOCIATION OF BIOTECHNOLOGY LED ENTERPRISES (ABLE)

No.123/C, 16th Main Road 4th Block, 5th Cross, Koramangala, Bangalore-560034, India.

Tel.: +91-80-41636853 Website: www.ableindia.in



Engage with India's \$200 billion BioEconomy

G S Krishnan,
Hon. President - ABLE

India's biotech has been making steady progress since the Covid-19 days and the \$200 billion Bio-Economy is poised to touch \$300 billion by 2030. India has been at the forefront of using all tools available from biotech field to Feed the world, Fuel the world and Heal the world in every possible way. Affordable vaccines, cost effective GLP1 class of drugs to treat the world's largest diabetic population and also control obesity, now made in India has been accepted very well by people.

As the world faces severe energy crisis since February 2026, India has offset some of the ill effects by 20% blending of ethanol in petrol and has taken the lead to introduce E85 fuels and pushing for Flex Fuel vehicles. Manufacturers are adopting sustainable process using BioSolutions through enzymatic and microbial technologies to usher in a Green India in many sectors.

India's innovation potential in biotech is now recognized and more than 150 companies have set up their Global Innovation Centres in our cities in the last few years to tap the immense talent pool of human resources. India is home to more than 11,000 biotech startups that are powering biotech innovations in many industrial segments to develop new products and services not just for the country's 1.4 billion people but for the world to make these solutions affordable and accessible to the entire humanity.

In a major breakthrough, India's Wockhardt has got the US FDA approval for a new class of antibiotics, Zaynich (Cefepime and Zidebactam) to treat complicated urinary tract infections in adults. Globally it is one of the first new antibiotic to get approval after many decades. Soon this product will be available to patients around the world.

We are showcasing some of our best companies in a large India Pavilion (Booth nos. 3351 and 3551) for the global industry to access them at one place. The India Biotech Handbook 2026, in your hands now, provides some glimpses into the country's biotech landscape. The ABLE team (www.ableindia.in) is around to guide you meet the Indian industry leaders to explore collaboration opportunities and also engage post event with the wider industry to connect for a greater Biotech Future.

We look forward to having you with us!



India's BioEconomy at a glance

India's BioEconomy Value 2025

\$195.3 bn

Growth (2024–2025)

18%

CAGR (2020–2025)

17.8%

GDP Contribution


4.8%

Total Biotech Startups

11,855

Bioeconomy Growth (2020–2025)

2020 \$86 bn	2021 \$106 bn	2022 \$137 bn
2023 \$151 bn	2024 \$166 bn	2025 \$195 bn



Manufacturing-led segments (BioIndustrial and BioPharma) account for nearly three-quarters of India's BioEconomy. Services-linked activities such as digital life sciences platforms and global capability centres are expanding rapidly.

Ecosystem Indicators

Core Biotech Workforce

350 - 400k

Life Sciences Workforce

3-3.5 Mn

Biotechnology Startup Ecosystem

Total Biotech Startups

11,855

New Startups In 2025

1,780

Investment Landscape

Total Deals

208

Total Investment

\$4.6 Bn

Investments in 2025

\$1.58 Bn

Private Equity Exits



45 companies

Exit Value

\$6.15 Bn+



Top 7 States contributing to 78% of the BioEconomy in 2025



KUMSHUNGBA PRIVATE LIMITED

SUSTAINABLE BIOMANUFACTURING



Biomanufacturing
made simple

Indirubin
Curcumin
Capsaicin



Personal care products with bioavailable lipids



Kumshungba Private Limited
Wangkhei Khunou Near Citizens Club
Imphal - 795005, Manipur, India
☎ 8974403193
✉ kumshungbam@gmail.com
🌐 www.kumshung.com


India's BioEconomy Outlook to 2035

GROWTH TRAJECTORY AND SEGMENTAL BREAKDOWN

From US **\$195 billion** in **2025**, India's BioEconomy is projected to cross US **\$300 billion** by **2030** and US **\$650 billion** by **2035**, driven by BioIndustrial leadership, BioPharma scale-up, BioServices acceleration, and digital-biological convergence. ABLE's policy advocacy, ecosystem reporting and global partnerships are central accelerants.



BioEconomy Growth Trajectory (\$ billion)



Sector outlook – 2035 projected share & growth drivers

BioIndustrial

46% share



Fermentation
Enzymes
Bioplastics
SAF

**Projected
CAGR ~18%
BioE3 policy
boost**

BioPharma

33% share



Biosimilars,
GLP-1,
Cell & Gene
Therapeutics

**Biopharma
SHAKTI
₹10,000cr
Patent Cliff**

BioAgri

8% share



Precision Agri
Biofertilisers
CBG
E20 mandate

**E20 mandate
IEA 2× biofuel
forecast**


BioServices

13% share



CRO/CDMO,
AI-drug
discovery

**Fastest
sector
66% growth
in 2025**



Challenges and the Need for Accelerated Growth

Despite substantial progress, several challenges remain. Biotechnology innovation involves long development timelines, significant capital requirements and complex regulatory processes. Many startups continue to face challenges in scaling technologies from proof-of-concept to commercial manufacturing.

India still requires:

- Greater access to growth capital
- Expanded pilot manufacturing infrastructure
- Faster regulatory approvals
- Stronger industry-academia collaboration
- Increased deep-tech investment
- Enhanced global partnerships
- Larger skilled talent pools



Global competition is also intensifying rapidly, with major economies making significant investments in biotechnology infrastructure, manufacturing and advanced research capabilities.

India's ability to accelerate commercialization and strengthen innovation ecosystems will therefore be critical in maintaining global competitiveness.


ABLE's contribution to India's BioEconomy Growth



ABLE has played an important role in supporting the growth of India's biotechnology ecosystem.

As India's leading biotechnology industry association, ABLE has consistently worked toward:

- ✓ Policy advocacy
- ✓ Industry–government engagement
- ✓ Startup ecosystem development
- ✓ International collaboration
- ✓ Market access support
- ✓ Biotechnology ecosystem mapping
- ✓ Industry networking and partnerships





One of ABLE's key contributions has been the development of the **India BioEconomy Report (IBER)**, which has evolved into one of the country's most important references on biotechnology-led economic growth. Developed in collaboration with BIRAC and supported by DBT, the report tracks biotechnology-enabled economic activity across multiple sectors.



ABLE has also contributed to state-level biotechnology ecosystem development through initiatives such as the **Karnataka BioEconomy Report** and **Tamil Nadu BioVision**.



Pioneering AI-biology dialogue, organizing precision agriculture, and space biomanufacturing sessions. Building talent pipelines for AI-native biotech and advocating indigenous AI model development on Indian datasets.



Flagging structural vulnerabilities (IPA/pharma feedstock crisis); facilitating CDC-ABLE AMR AI session; bridging new Labour Code awareness to biotech HR, ensuring the sector operates on a stable operational foundation through 2035.



International engagement has also remained an important focus area. Through initiatives such as the **India Pavilion** at the **BIO International Convention** and startup delegations to global markets, ABLE is helping Indian biotechnology companies build partnerships, attract investments and expand international visibility.



The organization continues to support **industry collaboration** through **conferences, conclaves, policy forums, international delegations** and **global engagement platforms**.



HIGHLIGHTS
OF
BIO 2025





**INDIA
DELEGATION
@BIO2026**

Chhaya Chauhan

Chief Manager &
Incharge-Incubation
Biotechnology Industry
Research Assistance
Council (BIRAC)
sped4.birac@nic.in

G S Krishnan

Hon. President
Association of Biotechnology Led
Enterprises (ABLE)
president@ableindia.org.in

Narayanan Suresh

Advisor
Association of Biotechnology Led
Enterprises (ABLE)
suresh@ableindia.org.in

Indrila Sengupta

Manager - Technical Support
Association of Biotechnology Led
Enterprises (ABLE)
indrilas@ableindia.org.in

Godson George Michael Rai.

Investment Strategist
Guidance Tamil Nadu
godson@investtn.in

**Poongumaran Panneer
Selvam**

Managing Director
TICEL Bio Park Ltd.
md@ticelbiopark.com

Kshitij Datta Rishi

Co-founder & COO
4basecare Precision
Health Pvt. Ltd.
kshitij@4basecare.com

Debanjana Dey

Senior Program Manager -
Technical
Biotechnology Industry Research
Assistance Council (BIRAC)
user-23@birac.nic.in

Balasubramanya S

General Manager Association of
Biotechnology Led Enterprises
(ABLE)
gm@ableindia.org.in

Pavana Praveen

Manager - Operations
Association of Biotechnology
Led Enterprises (ABLE)
pavanapr@ableindia.org.in

Lena Kannappan

Adviser - US Desk
Guidance Tamil Nadu
lena@investtn.in

**Mathivathani Revathy
Paramasivam**

Deputy Vice President
Guidance Tamil Nadu
mathivathani@investtn.in

Senthilkumar Vanarajan

Manager -
(Scientific/Bioprocess)
TICEL Bio Park Ltd.
scientific@ticelbiopark.com

Arun Luthra

Managing Director
Emerging Technologies
arun@amergingtech.com



Tarun Luthra

Head Marketing
Emerging Technologies
sales@emergingtech.com

Saurabh Narain

Associate Vice President -
Global Branding,
Digital & Marketing
Communication
Biocon Limited
saurabh.narain@biocon.com

Rajanikanth Rau

Sr Vice President
Biological E. Limited
Rajanikanth.Rau@biologicale.com

Ganesh Mishra

Asst. General Manager
Biological E. Limited
Ganesh.Mishra@biologicale.com

Martin Henehan

Chief Business Officer
Biological E. Limited
Martin.Henehan@bebiosol.com

Vishnu Nagaraj

CEO
Co-Founder
Carve Startup Labs (CSL)
vishnu@carvestartuplabs.com

Mukesh Kumar

Chief Scientific Officer
Clinixel Life Sciences
Pvt. Ltd.
mukesh@clinixel.com

Dhruv Taneja

Head - Portfolio Strategy
(Biologics & Generics)
Biocon Limited
dhruv.taneja@biocon.com

Sushanth Boda

Global Business Development -
Head of Advanced Markets
Biocon Limited
Sushanth.boda@biocon.com

ALN Reddy

Sr Vice President
Biological E. Limited
Reddy.ALN@biologicale.com

Narender Mantena

Director
Biological E. Limited
nmantena@biologicale.com

Jagan Mohan Reddy

Founder & CEO
BIOVARAM, UR Advanced
Therapeutics Pvt. Ltd.
jreddy@uratpx.com

Deepa Arora

Chief Executive Officer
Clinixel Life Sciences
Pvt. Ltd.
deepaarora@clinixel.com

Kamal Shahani

Managing Director
CRQA
kshahani@crqa.in



Vinayak Shahani

Vice President Business
Development
CRQA
vshahani@crqa.in

Supriya Kashikar

CEO
Genext Genomics Pvt. Ltd.
supriyakashikar@
genextgenomics.com

Pradeep Kumar Gupta

Vice President Research And
Development
Indian Immunologicals Ltd.
pradeep.gupta@indimmune.com

Manesh Thomas

CEO
Manipal-Government of
Karnataka Biocubator
ceo.biocubator@manipal.edu

Gurunath Angadi

COO
MM Activ Sci-Tech
Communications
gurunath.angadi@mmactiv.com

Jayachandran Ezhuthachan

Sr. VP,
Business Development & Alliance
MSN Laboratories Pvt. Ltd.
jay.ezhuthachan@cramsn.com

Ravi Vinayak

Head - Business Development
Provis Biolabs Pvt. Ltd.
bdusa@provisbiolabs.com

Dinesh Kundu

CEO & Co-founder
East Ocyon Bio Pvt. Ltd.
dinesh.kundu@eastocyonbio.com

Anand Kumar

Managing Director
Indian Immunologicals Ltd.
anandkumar@indimmune.com

Sarthak Vasudeva

Sr Vice President and Head -
International Business
Indian Immunologicals Ltd.
v.sarthak@indimmune.com

Shanthanu Chakravarthy

Co-Founder
MIMYK Medical Simulations
Pvt. Ltd
shanthanu@mimyk.com

Gopal Krishna Lakkireddy

Head of Biotech
MSN Laboratories Pvt. Ltd.
gopal.lakkireddy@msnlabs.com

Rajeev M Patil

Chief Technical Officer
Norwich Clinical Services Pvt. Ltd.
Rajeev.patil@norwichclinical.com

Chirag Shah

Head-Clinical Operations
Raptim Research Pvt. Ltd.
chirag.shah@raptimresearch.com

Sonela Cavicke

Head of Discovery Business
Development, North America
Sai Lifesciences Ltd.
sonela.c@sailife.com



Subhash Narayanan

Founder CEO & CTO
Sascan Meditech Pvt Ltd
subhash@sascan.in

Puspadhwaja Mall

Vice President
Shilpa Biologicals Pvt. Ltd.
puspadhwajam@shilpabio.com

Andrew George

Sr. Business Development
Manager
Shilpa Biologicals Pvt. Ltd.
andrew.g@shilpabio.com

Abhinav Dhandia

CEO
Sphaera Pharma
Abhinav.d@sphaerapharma.com

Shantanu Patil

Director, Directorate of
Entrepreneurship & Innovation
SRM Institute of Science &
Technology (SRMIST)
director.dei@srmist.edu.in

Goutam Das

Managing Director
TCG Lifesciences Pvt. Ltd.
Goutam.das@tcgls.com

Subho Roy

Sr. Vice President & Business
Head - CDMO
TCG Lifesciences Pvt. Ltd.
subho.roy@tcgls.com

Senthil Kumar Murugesan

CEO Co-Founder
Savemom Private Limited
senthilm@savemom.in

Shriya Khandwe

Vice President, Business
Development
Shilpa Biologicals Pvt. Ltd.
shriya.k@vbsilpa.com

Ayda Onat Orallar

Business Development
Consultant
Shilpa Biologicals Pvt. Ltd. ayda.
onat@vbsilpa.com

Somdutta Sen

Head-R&D
Sphaera Pharma
Somdutta.s@sphaerapharma.com

BN Manohar

MD & CEO
Stempeutics Research
Pvt. Ltd.
manohar@stempeutics.com

Sanjoy Mohanty

Vice President, Head of Business
Development
TCG Lifesciences Pvt. Ltd.
sanjoy.mahanty@tcgls.com

Sarah Chatterjee

AVP Business Development
TCG Lifesciences Pvt. Ltd.
sarah.chatterjee@tcgls.com



Sathyabalan Murugesan

Co-Founder & Director
Theertha Biopharma Pvt. Ltd.
sathya@theerthabiopharma.com

Shougandh Ghosh

Director Quality System
Theertha Biopharma Pvt. Ltd.
shougandh@theerthabiopharma.com

Yashas Chandra

Executive Director
Vipragen Biosciences
Pvt. Ltd.
yashas.c@vipragen.com

Raj Bhanushali

Chief Commercial Officer
Yashraj Biotechnology Ltd.
raj@yashraj.com

Shilen Patel

Head of Business Development -
USA
Yashraj Biotechnology Ltd.
Shilen.Patel@yashraj.com

Nivedha Krishnan

Head-Project Management
Theertha Biopharma Pvt. Ltd.
nivedha@theerthabiopharma.com

S. Chandrashekar

Chairman and Managing Director
Vipragen Biosciences Pvt. Ltd.
chandra@vipragen.com

Yashwanth Kurnool

Senior General Manager -
Business Development
Vipragen Biosciences Pvt. Ltd.
yashwanth.kurnool@vipragen.com


Amit Khanna

Vice President – Integrated Drug
Discovery and Development
Yashraj Biotechnology Ltd.
amit.khanna@yashraj.com



India Pavilion at BIO International Convention

SAN DIEGO 2026



BOOTH # 3351

4basecare Precision Health

Amerging Technologies

Bhami's Research Laboratory

Biocon Limited

Clinixel Life Sciences

CRQA

East Ocyon Bio

GeNext Genomics

Guidance Tamil Nadu & TICEL

BIOPARK - Government of

Tamil Nadu

IKP Knowledge Park

Indian Immunologicals

Karnataka Innovation
& Technology Society,
Department of Electronics, IT &
Bt, Government of Karnataka

MIMYK Medical Simulations

MM Activ Sci-Tech
Communications

MSN Laboratories

Norwich Clinical Services

Provis Biolabs

Raptim Research

Sai Lifesciences

Shilpa Biologicals

Sphaera Pharma

SRMIST (SRM Institute of
Science and Technology)

Stempeutics Research

TCG Lifesciences

Theertha Biopharma

UR Advanced Therapeutics
(BioVaram)

Veeda Lifesciences

Vipragen Biosciences

Yashraj Biotechnology

BOOTH # 3551

AAARNA Therapeutics

Amogen Pharma

Balrampur Chini Mills Ltd.

Biological E

Biotechnology Industry
Research Assistance Council
(BIRAC)

Fermbox Bio

HiMedia Laboratories

IPCA Laboratories

Kodo Lifescience

Miltenyi Biotec India


Morepen Laboratories

Pandorum Technologies

Revelations Biotech

Synthimed Labs

Vimta Labs Limited



able

Pursuing
Infinite
Opportunities

Association of Biotechnology Led Enterprises





San Diego Convention Center
June 22-25, 2026

**DRIVEN
BY PURPOSE**

India Pavilion Inauguration

Booth #**3351 & 3551**

June 22, 2026 | 12:30 Hrs



BioVoices @ India Pavilion

June 23, 2026 | 02:00 PM onwards

India Pavilion Exhibition Reception

June 23, 2026 | 05:00 - 06:30 PM



Scan the QR Code
to access BIO Schedule

Bio International Convention
June 22-25, 2026 | San Diego, CA





India Pavilion Exhibitors



Backed by: **illumina** & **Infosys**

REDEFINING CANCER CARE THROUGH DATA-DRIVEN GENOMIC INTELLIGENCE

4baseCare is a data-driven precision oncology company building one of the most inclusive cancer intelligence platforms emerging from the Global South. By sequencing thousands of patients, we are generating large multimodal oncology datasets linked to a uniquely annotated biobank, creating a strong foundation for research, biomarker discovery, and real-world clinical decision

15+ COUNTRIES



25000+ PATIENTS

These assets power differentiated platforms such as the *Global Cancer Diversity Atlas* **GCDA** and **OncoTwin**, our AI-enabled clinicogenomic platform designed to derive actionable insights from patient similarity and outcomes data.

4baseCare has also been selected for the *MSK Innovation Hub Challenge 2025* Cohort at *Memorial Sloan Kettering Cancer Center*, USA. This milestone enables validation of OncoTwin Insights on 30,000 deidentified MSK patient records, advancing our goal of making the platform clinic-ready for doctors worldwide. This expands relevance across cancer types and emerging care settings.

● Key Data & Milestones

- **70+ cancer types | 12+ rare cancers | 8+ countries.**
- **25,000+** genomic profiles from underrepresented populations with corresponding longitudinal RWE data and Whole Slide Images for a significant number of samples
- **GCDA:** A diversity-first cancer atlas from the Global South.
- **OncoTwin:** Selected for **MSK iHub Challenge 2025 Cohort.**
- Powered by peer-reviewed science and real-world oncology data
- **7 Labs** across Global South and Middle-East

● Why Partner with Us?

- **Data Others Don't Have:** Unique Global South oncology insights at scale
- **More Than Testing:** Genomics + AI + real-world evidence in one platform
- **Built for Real Clinical Impact:** OncoTwin turns patient similarity into actionable insights
- **Designed to Scale:** From biomarker discovery to trial optimization and decision support
- **Globally Validated | Locally Relevant:** Backed by leading partners. Built for emerging markets.

JOIN THE PRECISION ONCOLOGY REVOLUTION



To Partner with us, Contact: **Kshitij D. Rishi**
COO & Co-founder, 4baseCare
✉ kshitij@4basecare.com

Visit Our Website:
www.4basecare.com

Scan Here →



LEADING BIOPROCESS EQUIPMENT MANUFACTURER



PLANT DESIGN

Amerging technologies have inhouse process design engineers with over 15 years of experience who can design the upstream & downstream process



MANUFACTURING

With our immense experience in the field and our state of the art manufacturing facility we provide the best in class fermenters



TURNKEY SOLUTION

We offer the most cost efficient & reliable extensive project solutions for your technology & plant implementation

ABOUT US

Founded in 2012, Amerging Technologies has rapidly emerged as a leading manufacturer of bioprocess equipment in the industry. Our strong reputation is based on our unwavering focus on quality, value, and exceptional after-sales services.

With a foundation in engineering expertise and innovation, we proudly serve a diverse range of industries, including biotech, pharmaceuticals, biofertilizers, and more. Our core commitment has always been to ensure customer satisfaction. Operating with a customer-centric approach, we aim not only to meet but to surpass expectations. We believe that transparent and ethical business practices pave the way for lasting mutual success.

AMERGING TECHNOLOGIES



sales@amergingtech.com
sales2@amergingtech.com




+91-7743008391



www.amergingtech.com



Bhami's SubQ mAb Delivery



BRL's SubQ technology enables **high-concentration, low-viscosity** mAb formulations for subcutaneous administration.

High-Concentration mAb Delivered Subcutaneously

**250 - 300
mg/mL**

**Between 20-50 cP
Viscosity**



Pre-filled
Syringe



High-Concentration
mAb Formulations




On-Body
Autoinjectors (OBI's)

**2 - 10 mL
SubQ mAb
delivery**

**Pre-filled syringe
& On-body injectors**



**US & EU Patented
Universal GRAS Excipients**
One combination platform
for any mAb / protein



High Stability
Robust across storage
and stresses




Visit our
website




Download
Product
Information



**Bhami's
Research
Laboratory**

RESEARCH | INNOVATION | DRUG DELIVERY

Bhami's Research Laboratory (BRL)
is a science-driven biotherapeutics
R&D company focused on solving
complex drug delivery challenges.

 www.bhamilab.com
 vinayak@bhamilab.com

Delivering affordable, life-changing medicines to patients everywhere

Diabetes | Oncology | Immunology
Obesity | Ophthalmology | Bone Health
Cardiology | Central Nervous System

21+ million patients benefited
across **120+ countries***

*through generics and biosimilars (FY25)



www.biocon.com



Scaling Science. Expanding Access.



A global partner for vaccines, biologics, and complex injectable
— from development to commercial supply.



- ✓ Biological E. Limited, founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in South India
- ✓ Supplied more than Five billion doses of vaccines for global health. Leading supplier of several life-saving vaccines and pharmaceutical products to UNICEF, PAHO and many other global markets
- ✓ Equipped with state-of-the-art laboratories, R&D facilities, and more than 5,000 highly skilled employees, including around 350 scientists
- ✓ Our facilities comply with rigorous compliance standards established by USFDA, EMEA, WHO, ANVISA Brazil, TGA Australia and other regulatory bodies
- ✓ Our integrated services platform encompasses Microbial, Conjugate, Cell Culture, mRNA, Nanotechnologies (Liposome, Nanoparticles, Microemulsion), Peptides, Iron Colloidal, LMWH, Emulsion & Suspension
- ✓ Our expertise in technology transfer, process development, and commercial manufacturing enables us to aid clients across various stages of their journey
- ✓ We offer seamless end-to-end Contract Development and Manufacturing Organization (CDMO) services for biologics, covering process development to clinical and commercial GMP manufacturing of drug substances at BSL-2 and Fill-finish
- ✓ Our aseptic fill/finish manufacturing capabilities include Liquid and Lyophilized platform technology for vial, ampoule, PFS, cartridge, auto-injectors, and multiple drug-device combinations, as well as Secondary Packaging
- ✓ We are leading in the manufacture of vaccines and biopharmaceuticals. Our specialty lies in in-licensing and co-development, which aid us in accelerating the production of next-generation vaccines and RNA therapeutics

Vaccines & Biologics | Branded Formulations | Speciality Generic Injectables

www.biologale.com



CLINEXEL services — Clinical Trial Project Management, Clinical Operations, Regulatory, Clinical Data Management & Biostats, Medical Writing, and Safety Monitoring

- ④ CLINEXEL is a full-service clinical research organization (CRO)
- ④ Management Team with extensive experience in leadership positions in large pharma and MNCs brings extensive global pharmaceutical and clinical research expertise.
- ④ Strong experience of the team in early drug development, including clinical strategy and regulatory negotiations
- ④ Specialized expertise in managing complex clinical trials across ICU-based, hospital, and outpatient settings
- ④ Experienced team with strong operational efficiency, regulatory compliance, and scientific oversight
- ④ Proven capability in global project management, enabling harmonized trial execution, standardized quality systems, and coordinated oversight across multiple geographies.
- ④ Strong track record in delivering timely and cost-effective studies while maintaining adherence to ICH-GCP and international regulatory requirements.
- ④ CLINEXEL offers specialized expertise in rescue trials, managing critically ill and treatment-refractory patients across clinical settings.. Its regulatory, operational, and scientific capabilities support accelerated, high-risk clinical development programs, led by Dr. Deepa Arora, CEO, and Dr. Mukesh Kumar, CSO of CLINEXEL.
- ④ Therapeutic expertise includes oncology, infectious diseases, gastroenterology, cardiometabolic disorders, ophthalmology, dermatology, cardiovascular, and renal diseases.
- ④ Full member of AICROS, supporting multi-regional clinical trials through a global CRO alliance with local regulatory expertise and high-quality execution.



www.clinixel.com



info@clinixel.com



CRQA (Compliance, Regulatory & Quality Assurance) is an independent, specialized GxP auditing and regulatory consulting organization

CRQA (Compliance, Regulatory & Quality Assurance) is an independent, specialized GxP auditing and regulatory consulting organization headquartered in Noida/New Delhi, India, and a unit of Tenet Health Edutech Pvt. Ltd.

Built exclusively around GxP compliance, CRQA serves pharmaceutical, biotechnology, medical device companies, CROs and healthcare institutions across more than 60 countries and in 30 languages, through a global network of regionbased auditors.

Free from conflicts of interest, CRQA does not run clinical trials or CRO operations, ensuring objective audits and consulting across GCP, GLP/GCLP, GMP, GDP, GVP/pharmacovigilance, BA/BE,

medical devices, computer system validation, QMS, SOPs and compliance training. Certified to ISO 13485 and ISO 9001:2015, DUNS registered and MSME recognized in India, CRQA is a credible partner for inspection preparedness (FDA, EMA, CDSCO), quality system development, and global regulatory support from feasibility to dossier filing.

At BIO 2026, CRQA offers life sciences innovators a scalable, costefficient and independent compliance solution for new market entry, vendor oversight and sustained inspectionreadiness across multiple geographies.



www.crqa.in



bd@crqa.in



BIO INTERNATIONAL 2026

EAST OCYON BIO

Allogeneic Cell & Gene Therapy | India

Have Phase I Data In US/EU ?

BRING YOUR CGT ASSET TO INDIA

India Phase II pathway | CGT manufacturing | Local executive partner



Designed for late or completed Phase I assets supported by mature safety data

About Us

East Ocyon Bio is developing off-the-shelf CAR-NK and CAR-gamma delta T platforms for solid tumors, autoimmune and rare diseases, supported by in-house cell expansion, vector, analytical and translational capabilities.



WHY EAST OCYON BIO ?

- India's First off-the-shelf CGT
- Integrated vector+ cell therapy
- Cost-engineered manufacturing
- 5 patents filed



Cell Culture



Immune cell engineering



BSL-2



Aseptic processing

- Supported by DBT/BIRAC & TDB/DST
- Bharat Innovates Top 100
- Global Startup Award Winner



+91-9726842660



renu.kundu@eastocyonbio.com




www.eastocyonbio.com

From Target to Therapeutic Candidate

Integrated antibody discovery and engineering support for next-generation biologics.

GeNext Genomics supports the discovery, engineering, and development of high-quality antibody-based therapeutics.



Therapeutic innovation requires molecules that are specific, potent, developable, and scalable.

GeNext Genomics brings together antibody discovery, engineering, characterization, and development support to help advance therapeutic programs from early concept to candidate selection.



ANTIBODY DISCOVERY

Generation and screening of antibodies against therapeutic targets.



ANTIBODY ENGINEERING

Optimization for affinity, specificity, stability, and developability.



FUNCTIONAL CHARACTERIZATION


Assessment of binding, potency, selectivity, and mechanism-relevant activity.



LEAD CANDIDATE SUPPORT

Support for lead selection, optimization, and preclinical development readiness.

OUR INTEGRATED APPROACH



THERAPEUTIC AREAS WE SUPPORT



Oncology



Autoimmune Disorders



Inflammatory Diseases



Infectious Diseases



Rare Diseases

WHY PARTNER WITH GeNext Genomics?

- ✓ Target-focused antibody discovery
- ✓ Recombinant technology-driven development
- ✓ Custom workflows for each therapeutic program
- ✓ Early developability consideration
- ✓ Scalable approach from research to development



Advance your therapeutic antibody program with
GeNext Genomics.

✉ Email: info@genextgenomics.com
🌐 Website: www.genextgenomics.com
📍 Location: Nagpur, India



KARNATAKA INNOVATION AND TECHNOLOGY SOCIETY is a society duly registered under the Karnataka Societies Registration Act, 1960.

KARNATAKA INNOVATION AND TECHNOLOGY SOCIETY is a society duly registered under the Karnataka Societies Registration Act, 1960.

KITS assists the Department of Electronics, IT, Bt, and S & T, Government of Karnataka in the following:

- ④ Create an enabling ecosystem to develop Information technology, Biotechnology and Electronics and Semiconductor industry in the state through policy facilitation and investment promotion.
- ④ Promote startups and entrepreneurs to encourage innovation.
- ④ Generate employment for the state's talent by taking up-skilling and re-skilling people to create a ready pool of talent for the industry.
- ④ Interface with industry, academia, and R&D institutes on various matters of interest, emerging technology areas,

and collaboration with other countries/cities through Global Innovation Alliance (GIA)

KITS focuses on the vast technology sector by handling its various sub-components through separate policies:

1. Information Technology (IT) Policy 2025-30
2. Startup Policy 2025-30
3. AVGC-XR Policy 2024-29 : Animation, Visual Effects, Gaming, and Comics – eXtended Reality
4. **ESDM Policy:** Electronics System Design and Manufacturing and Special Incentives
5. Biotechnology Policy 2024-29
6. Data Centre Policy 2022-27
7. Cybersecurity Policy 2024-29
8. Global Capability Center (GCC) Policy 2024-2029
9. Karnataka Space Policy 2025-30



k-tech.karnataka.gov.in

IKP KNOWLEDGE PARK



IKP Knowledge Park is India's first science park and incubator ecosystem spread over 200 acres in Hyderabad's renowned Genome Valley. It also operates India's first hardware incubator and makerspace in Bengaluru.

As a leading hub for life sciences, deeptech, and innovation, IKP brings together startups, researchers, and global industry leaders under one ecosystem. The Park in Hyderabad hosts renowned R&D-driven companies including US Pharmacopeia, Sai Life Sciences, IFF, ADAMA, Laurus Labs, and Daicel Chiral Technologies, making it a vibrant destination for cutting-edge research, collaboration, and commercialization.

BioLabs & Bio-NEST

ISO7-certified wet labs enabling rapid validation, clinical pathways, and collaborative R&D for deep-tech ventures.



Biomufacturing & Scale-up:

Biomufacturing infrastructure supporting biotech startups from early development to pre-commercial readiness.

SmartFab

From concept to production, access a wide array of specialized fabrication services under one roof.



IKP ARK

IKP's leading co-accelerator is an embedded co-building platform for TRL 3+ deep-science ventures across productization, regulatory, manufacturing, and fundraising.

BFI Biome

In partnership with Blockchain for Impact (BFI), IKP supports and handholds biomedical startups & innovators in their productization journey.



IKP-BIRAC EDGE

Centre for Internationalization:

Enabling global market access, soft-landing partnerships, and internationalization for Indian deep-science startups.

SOME OF OUR BIOTECH STARTUPS



PARTNERSHIPS



Gates Foundation



OUR IMPACT

1350+
Unique
startups
supported

\$28.08 M
Grant
funding
deployed

\$417.80 M
Funds
raised by
IKP Startups

15,000+
Direct
high-skilled
jobs created

60,000+
Indirect
jobs





CDMO

LICENSING

MARKETING

a One Health company

- 5 Bn doses produced till date
- 90 Mn doses of Human vaccines produced last year
- Touching 250000 Human lives everyday
- 492 Mn doses of animal vaccines produced last year
- Touching 13 Mn animal lives everyday
- Leadership in Human & Animal Health vaccines
- Multi product, multi dosage forms capability
- Multispecies viral & bacterial facility
- State of the art BSL3 facility
- 4 Manufacturing facilities globally

Human Vaccine Portfolio

Hep A | Td | MR | Rabies | DPTHiHepB | Hep B | DPT | TT



LEADERSHIP

AGILITY

ENABLER

MIMYK

Innovating in
Medical Product Design
and Development

DESIGNED FOR PEOPLE

Medical products that
are useful, usable and
engaging.

DESIGNED FOR HEALTHCARE

Integrate seamlessly with
clinical environments
and workflows.



Scan to
see our work

www.mimyk.com
contact@mimyk.com

INNOVATION + SYSTEM DESIGN + INTEGRATED SOLUTIONS + ARTIFICIAL INTELLIGENCE



BENGALURU TECH SUMMIT 2026

Bangalore International Exhibition Centre
November 17-19, 2026

Get ready for Asia's Largest Integrated Technology Event!

WHERE BIOTECHNOLOGY MEETS INNOVATION & IMPACT

The **29th** edition of the **Bengaluru Tech Summit (BTS)** will take place from **17-19 November 2026** at the **Bangalore International Exhibition Centre (BIEC)** under the theme **'AI & Beyond'**. An initiative of the Department of Electronics, Government of Karnataka, in partnership with industry stakeholders, BTS is a premier global platform showcasing Karnataka and Bengaluru as innovation hubs, bringing together industry leaders, researchers, startups, investors, and policymakers from around the world.

BTS 2026 IN NUMBERS



75+

Countries



30+

States & UTs of India



1000+

Tech Startups



1800+

Exhibitors



120+

Sessions



700+

Speakers



25,000+

Delegates



60,000+

Business Visitors

OPPORTUNITIES FOR THE BIOTECH & HEALTHTECH SECTORS

FOCUS PAVILION

A Pavilion built for Biotech & Healthtech Organisations to showcase breakthrough innovations and connect with the right ecosystem.

THEMATIC CONFERENCE TRACK

Transforming healthcare through AI-enabled diagnostics, precision medicine, biotech breakthroughs, and digital health innovation.

BTS 2026 HIGHLIGHTS

- Multitrack Conference • International Exhibition • Future Makers Conclave • Global Innovation Alliance
- India-USA Tech Conclave • India Innovation Alliance • Industry Roundtables • Awards • Startup & Investor Awards
- Startup Pitching and Mentoring • Global CEO Conclave • Product Launches • Quizzes • B2B and B2G Partnering
- Poster Showcase • Masterclass Series

AI & BEYOND



FOLLOW US ON



@blrtechsummit

SCAN TO KNOW MORE

MSN Laboratories is one of the fastest-growing research-based and fully integrated pharmaceutical companies, headquartered in Hyderabad, India. For over 20 years, MSN has strengthened its presence across APIs, generic formulations, contract services, and biologics through innovation and quality excellence. Today, MSN serves 100+ countries with a commitment to accessible and affordable healthcare worldwide.

cGMP facility:

- Microbial cGMP facility with multi-scale reactor capabilities.
- 2 lakh sq. ft. state-of-the-art mammalian cGMP facility.
- Single-use reactor-based drug substance manufacturing capabilities.
- Experienced team driving process development, manufacturing, and regulatory operations.

R&D Capabilities:

- Expertise in process development, analytical development, and CMC operations.
- Integrated microbial and mammalian cell culture capabilities for in-house and contract projects.
- Advanced analytical testing and characterization capabilities.



MSN Corporate: H. No. 2-91/10 & 11 /MSN, Whitefields,
Kondapur, Hyderabad, Telangana, India-58.

www.msnlabs.com | Follow us on:     

biotech@msnlabs.com

Provis

Recombinant Bioreagents for Research & Biomanufacturing



High
Purity



Superior
Activity



Low
Endotoxin



Animal
Origin Free



Lot
Consistency



Research &
GMP Grades

Provinase[®] Endonuclease

High-performance
nuclease for DNA
removal in Cell & Gene
Therapy manufacturing.

Applications

- ✓ Cell & Gene Therapy
- ✓ Viral Vector Manufacturing
- ✓ Recombinant Protein Production
- ✓ Vaccine Manufacturing
- ✓ Plasmid & mRNA Manufacturing

Our Recombinant Bioreagents

NUCEASES

- Provinase[®] Endonuclease

GLYCOENGINEERING ENZYMES

- PNGase F
- PNGase F Flash[™]

PROTEASES

- Trypsin
- Enterokinase
- Carboxypeptidase B
- Kex2

AFFINITY PROTEINS

- Streptavidin

RECOMBINANT PROTEINS

- Recombinant Albumin
- Recombinant Insulin



Additional custom enzymes & proteins
available to support your process needs.

About Provis

Provis Biolabs develops and manufactures recombinant bioreagents, peptides, and CDMO solutions for global life science and biopharmaceutical applications.

Contact Us

USA Office

- 📍 East Hartford, CT, 06108, USA
- ✉️ bdusa@provisbiolabs.com
- ☎️ +1 (650) 996-4951

India Office

- 📍 Hyderabad, Telangana, India
- ✉️ bd@provisbiolabs.com

YOUR FIRST-CHOICE CRO IN INDIA

To Execute Clinical Research in India

Clinical Research Built on Quality, Compliance & Trust

Our Service

- ✓ Pharmacovigilance
- ✓ Bioavailability & Bioequivalence Studies
- ✓ Bioanalytical Services
- ✓ Corporate Training
- ✓ Medical writing



REGULATORY ENDORSEMENTS

Audited by Major Regulatory Agencies:



WHY NORWICH CLINICAL SERVICES

- ✓ Vast Experience
- ✓ Strong Leadership
- ✓ Focused on Quality
- ✓ Impeccable Track Record

CONTACT US

📍 #147/F, 8th Main, 3rd Block, Koramangala,
Bangalore – 560 034, Karnataka, India

✉ bd@norwichclinical.com

🌐 www.norwichclinical.com



We are the **CRO** of first-choice **in India**



FULL SERVICE GLOBAL CRO

Numbers That Build Confidence



21

Years of
Trusted Legacy



40+

USFDA Inspections
Supported



1000+

Clinical Sites Across
Therapeutic Areas



10k+

Patients Managed
Across Studies



700+

Employees

Experience Across Multiple Therapeutic Areas



Oncology



Dermatology



Cardiology



Neurology/
Psychiatry



Gynecology



Respiratory

Our Services



Clinical Trials
(Phase I - IV)



Data
Management



Bio
Statistics



Regulatory
Services



Invitro
Services

Advancing clinical research through end-to-end
trial support across diverse therapeutic areas





A trusted partner in bringing new medicines to life. **Fast.**

Sai Life Sciences is a full-service Contract Research, Development & Manufacturing Organization (CRDMO) working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules and emerging modalities. With operations across India, the UK, and the US, Sai Life Sciences offers deep scientific expertise, world-class infrastructure, and a culture of excellence focused on quality, safety, and sustainability.

26 years
& counting

Full service
CRDMO

Global presence
with sites in USA, UK & India

>300
active customers
across biotech,
small & mid
and big pharma

**19 of the
top 25**
large pharmaceutical
companies work with us

3800+
strong talent pool





An integrated biopharmaceutical company dedicated to advancing human and animal health through science-driven innovation.

Shilpa Biologicals Private Limited, a fully owned subsidiary of Shilpa Medicare Limited, is an integrated biopharmaceutical company headquartered in Dharwad, India, dedicated to advancing human and animal health through science-driven innovation. Operating at the intersection of development and manufacturing, Shilpa Biologicals provides end-to-end solutions that span the entire biopharmaceutical value chain.

As a hybrid Contract Development and Manufacturing Organization (CDMO), Shilpa Biologicals provides comprehensive services including mammalian and microbial fermentation, upstream and downstream process development, analytical characterization, and high-volume fill-finish capabilities for vials and pre-filled syringes. Complementing these

capabilities is a dedicated Antibody-Drug Conjugate (ADC) end-to-end manufacturing facility from payload linker development to Bioconjugation to fill and finish, purpose-built to deliver end-to-end oncology therapeutics production using deep high-potency compound expertise.

Shilpa Biologicals' proprietary biosimilar pipeline spans monoclonal antibodies, fusion proteins, and specialty biologics across immunology, oncology, and hematology — available as off-the-shelf formulations ready for B2B licensing and commercialization. A standout in its portfolio is Recombinant Human Albumin, a novel, virus-free blood product alternative produced through a safe, non-human expression system. Through its out-licensing platform, Shilpa Biologicals partners with global pharmaceutical companies to bring these innovations to patients worldwide.



www.shilpabio.com



madhav@vbszilpa.com

SPHAERA

Innovation for Patients

Your embedded innovation partner from concept to clinic.

We integrate science, technology and agility to co-create and accelerate high-impact therapies.



**Embedded
Collaboration**



**Translation
Focused**



**Agile and
Responsive**



**Platform
Enabled**

WE PARTNER TO CREATE VALUE

5+

Projects
Advanced To
The Clinic

\$1bn+

value created for
partnered/
collaborative
programs

25+

R&D programs
advanced through
preclinical
discovery

OUR INTEGRATED CAPABILITIES



**DISCOVERY
CHEMISTRY**



**IN VITRO &
IN VIVO**



**PK/PD
ADME**



**ANALYTICAL
SUPPORT**



www.sphaerapharma.com



bd@sphaerapharma.com



SRM
INSTITUTE OF SCIENCE & TECHNOLOGY
(Deemed to be University u/s 3 of UGC Act, 1956)

SRM Institute of Science and Technology (SRMIST)

A leading multidisciplinary private university in India with over **60,000 students and 3,600 faculty members.**

The University offers Undergraduate, Postgraduate, and Doctoral programs in Engineering, Management, Medicine & Health Sciences, Science and Humanities, Law, and Agriculture, and is recognized as a Category-I University by the Ministry of Education, Government of India.

SRMIST actively promotes innovation, entrepreneurship, technology transfer, and industry collaboration.

SRM Medical College Hospital and Research Centre hosts the Biotechnology Industry Research Assistance Council (BIRAC) funded **BioNEST @**

SRM MCH to support Innovations in Biotechnology and MedTech through incubation, mentorship, research infrastructure, and industry connect.

The University has been granted the **AIC SRM Incubation Forum** under the Atal Innovation Mission, NITI Aayog, supporting start-ups in E-mobility, Defence Technology, and Cyber Security.

SRMIST's entrepreneurship ecosystem is bolstered by **Bootstrappers' Research Council (BRC)**, a Section 8 SPV. SRM BRC provides infrastructure, seed funding, training, mentorship, and laboratory access via the Directorate of Entrepreneurship and Innovation (DEI).



www.srmist.edu.in | www.srmdei.com

director.dei@srmist.edu.in

NAAC A++	UGC Category I with 12B Status	nirf (2025) World Ranking Ranked 1 st University	QS (2025) World Ranking one among 54 Indian Universities	THE WORLD UNIVERSITY RANKINGS (2025) World Ranking one among 91 Indian Universities	SHANGHAI RANKING (2025) World Ranking Ranked 8-9 in Indian Universities	nature INDEX (2025) World Ranking one among 18 Indian Universities	Green Metric (2024) World Ranking one among 3 Indian Universities
--------------------	---	--	---	--	--	---	--



stempeutics

Regenerating Hope

Stempeutics is a leading regenerative medicine company focused on the development and commercialization of novel cell-based therapeutics, with deep expertise in mesenchymal stromal cell platforms. Founded in 2006 by the Manipal Education & Medical Group, the company has built strong capabilities across scientific innovation, clinical development, GMP manufacturing, and commercialization.

Flagship Innovation: Stempeucel[®], is an off-the-shelf allogeneic mesenchymal stromal cell therapy derived from the bone marrow. It has received market authorization in India for Critical Limb Ischemia (CLI) and Knee Osteoarthritis (OA) and is recognized as the first innovative stem cell-based product to receive marketing approval in India.

Products and Pipeline in India

Stempeucel [®] Drug	R&D	Pre-Clinical	Phase 1	Phase 2	Phase 3	Marketing Authorization/Phase 4
CLI-BD Critical Limb Ischemia	→					
CLI-PAD Critical Limb Ischemia	→					
OA Knee Osteoarthritis	→					
DFU Diabetic Foot Ulcer	→					
Perianal Fistula (PAF) due to Crohn's Disease	→					
CLBP - Chronic Low Back Pain	→					
aGVHD - Acute Graft versus Host Disease	→					

Global Credentials: Stempeucel[®] is classified as an Advanced Therapy Medicinal Product (ATMP) and designated as an Orphan Drug by the European Medicines Agency for CLI due to Buerger's disease. Crossed critical regulatory milestones in US & Japan.

Manufacturing & Partnerships: With a GMP-certified manufacturing facility in Bengaluru and commercialization partnerships with leading pharmaceutical companies such as Cipla and Alkem, Stempeutics is advancing access to innovative regenerative therapies in India while expanding development opportunities in global markets.

International Development: In Japan, Stempeutics is advancing development of Stempeucel[®] for chronic limb-threatening ischemia through a collaboration with MEDINET Japan.

Innovation & Scientific Leadership:

100+ patents filed, 50+ patents granted Globally including US/Europe/Japan
90+ peer reviewed scientific international publications

From Concept to Commercialization —

Your Integrated Biologics Development Partner



 BIOSIMILARS	 RECOMBINANT PROTEINS	 PLASMID DNA	 LIPOSOMAL DRUG DELIVERY	 EXOSOME DRUG DELIVERY
---	--	---	---	---

Scan to know more



www.theerthabiopharma.com

Meet us at **US BIO**
BOOTH NO. 3181-513



END-TO-END DEVELOPMENT CAPABILITIES

	Discovery & Project Evaluation Early-stage research and feasibility assessment to de-risk your project.	 One Partner. Endless Solutions. Accelerating Affordable Biologics for Global Markets.
	Clone Development / Cell Bank Robust cell line development and well-characterized cell banks.	
	Process Development Scalable, efficient and cost-effective process development.	
	Analytical Development Advanced analytics ensuring quality, safety and consistency.	
	Scale-Up & Optimization Seamless scale-up with continuous process optimization.	
	Technology Transfer Smooth transfer with knowledge capture and documentation.	
	Regulatory Support End-to-end regulatory guidance for global complexities.	
	GMP Manufacturing (Commercial Supply) cGMP manufacturing with uncompromised quality for clinical & commercial supply.	

PLATFORM TECHNOLOGIES

	BIOSIMILARS & RECOMBINANT PROTEINS <ul style="list-style-type: none"> • Microbial & Mammalian Platforms • High Expression Systems • Process Development to Technology Transfer
	PLASMID DNA <ul style="list-style-type: none"> • Research Grade Plasmids • GMP Supply • Endotoxin-Free, High Yield
	LIPOSOMAL TECHNOLOGIES <ul style="list-style-type: none"> • mRNA Encapsulation • Targeted Drug Delivery • Custom Liposome Development
	EXOSOME TECHNOLOGIES <ul style="list-style-type: none"> • Cosmetic Applications • Regenerative Medicine Platforms • Isolation, Characterization & Scalable Production

WHY GLOBAL PARTNERS CHOOSE THEERTHA

 Established 2019	 ISO Certified Facility	 25+ Scientists & Specialists	 Clients Across Asia, Middle East & Africa	 Projects in Singapore, UAE, St. Louis, Algeria, Malaysia, Thailand, USA	 Proprietary Liposome & Exosome Platforms	 First GMP Facility Under Development
--	---	---	--	--	---	---

FEATURED PIPELINE & COLLABORATION OPPORTUNITIES

Biosimilars	ODT & Plasmids	Exosomes	Drug Delivery
Insulin Analog	GMP Plasmid DNA	Exosome Supply	Liposomal mRNA
Streptokinase	ODT Raw Materials	Customized Exosomes	Targeted Delivery
Recombinant	Custom Plasmids	Regenerative Platforms	Encapsulated Services
More Proteins in Development	Research & GMP Solutions	Scalable Exosome Production	Pre-clinical Drug Delivery

WE ARE SEEKING

-  Co-development Partners
-  Licensing Partners
-  Regional Commercialization Partners
-  Strategic Investors



Delivering Integrated End-to-end Solutions
to your Discovery, Development, and Commercial Pipeline.

Fast, Reliable, Competent

Service Verticals

Discovery Biology



- Assay Development and High-Throughput Screening
- DMPK/ADME/PK/Bioanalysis
- *In-Vivo* Pharmacology
- Safety Pharmacology & Toxicology

Discovery Chemistry



- Medicinal Chemistry
- Library Synthesis
- Analytical Chemistry
- Compound Management

Process R&D & Scale-Up




- Custom & Asymmetric Synthesis
- Route Scouting /Process Development
- Kilo lab Scale-Up & cGMP Support

Manufacturing



- Custom cGMP API Manufacturing
- Process Optimization / Validation
- Technology Transfer & Commercial Supply
- US FDA Approved facility



TAMIL NADU

INDIA'S EMERGING GLOBAL LIFE SCIENCES HUB



Tamil Nadu is India's second-largest state economy with a GDP of USD 419 billion and the fastest-growing state in FY25 at 11.9%. has positioned itself as the natural gateway for global life sciences investment into India and the fast-growing Southeast Asian markets. With 400+ life sciences companies spanning pharma, biotech, medical devices and medical electronics, and recognition from the World Economic Forum as South Asia's first Advanced Manufacturing Hub, the State offers a uniquely integrated proposition for companies seeking to manufacture, innovate and export from India.

FLAGSHIP LIFE SCIENCES INFRASTRUCTURE

TICEL Bio Park (Chennai):

India's pioneering purpose-built biotechnology park at Taramani offering ready-to-occupy plug-and-play wet labs, shared instrumentation and incubation space, the landing pad of choice for global biotech entrants and scale-ups.

Bharat Biotech (Vandalur Cluster):

A 200-acre bioscience innovation and manufacturing hub one hour from Chennai, anchored by Bharat Biotech. Focus areas include vaccines, monoclonal antibodies, antibody drug conjugates, cell & gene therapy, insulin innovation, and AI-enabled drug discovery, phased across a biologics core and a MedTech & emerging-tech frontier.

Bienville (Chennai):

A 90,000 sq. ft. Phase-I innovation hub targeting LEED Platinum, featuring a Central Instrumentation Facility (genomics, proteomics, microscopy), a 25-unit startup incubator, BSL-2 containment suites, and a GMP compliant ISO Class 7/8 pilot manufacturing floor, engineered to translate discovery into commercial product.

TALENT AND R&D DEPTH

Tamil Nadu produces 12,000-15,000 biotech graduates annually with the lowest attrition rate in India (4-5%); the country's largest untapped life sciences talent pool. Skilled workforce spans across molecular biology & genetics (15,000+), analytical chemistry (16,000+), cell & microbial techniques, bioinformatics, drug discovery, regulatory & QA, clinical trials and MedTech engineering. The State is home to 98 agro-technology research stations, 70+ institutes offering pharma and biotech courses, and dense R&D clusters in life sciences, electronics and automotive, with 9-12% of India's digital/AI/ML talent concentrated here.

GLOBAL COMPANIES PRESENCE

Tamil Nadu hosts over 130 Fortune 500 companies, anchoring a deep bench of multinationals across the life sciences value chain. Global pharma and biotech majors including Pfizer, AstraZeneca, Sun Pharma, Piramal, Biogen, Bharat Biotech and Par Formulations, drive drug manufacturing and formulations, while Omron, B. Braun and Trivectra, lead medical devices and diagnostics. Supporting this core, Foxconn, Dell, Samsung, Lenovo, Samminia, Salcomp and Flextronics, supply precision electronics for MedTech; Schwinger Sterer, Bosch, Komatsu and Saint-Gobain provide heavy engineering, fabrication and materials; while TÜV SÜD, SGS, Vintu Labs, Avantree, SAMEER and Godrej Calibration deliver international-standard testing and calibration services.

PORTS, LOGISTICS & GLOBAL CONNECTIVITY

Tamil Nadu is structurally the closest Indian coast to Southeast Asia, the only east-coast launchpad to ASEAN. Four deep-water ports within 400 km (Chennai, Tutukudi, Kamarajar, V.O. Chidambaram) deliver cold-chain transit of 21 days to the US East Coast and 18 days to Europe, the fastest among Indian states. Chennai factories sit just 45-56 km from port, slashing inland freight by over 80% versus west-coast clusters. Any location in Tamil Nadu is within 3 hours of an airport, with new greenfield airports at Chennai (Parandur) and Hosur underway and direct global connectivity to San Francisco, New York, London, Singapore, Dubai, Tokyo and beyond.

GOVERNANCE & FACILITATION

Guidance Tamil Nadu, India's pioneering investment promotion agency (est. 1992), is the single point of contact across the live star lifecycle-pre, ante and post establishment. The Single-Window Clearance System guarantees EC, DTCP and PCB approvals in 30-45 days, and Fire, Power, BSL, TNE and Public Health clearances in 15-30 days, with deemed approvals if timelines are exceeded. A dedicated Fast Track Cell offers weekly compliance reviews and direct ascension to the Chief Minister's Office. Services span investment facilitation, policy formulation, industry-academia linkages, trade missions, export promotion and supply-chain localisation-delivering the predictably global investors expect.

Partner with Tamil Nadu at BIO US 2026 — where global ambition meets India's most enabling life sciences



UR Advanced Therapeutics Pvt. Ltd.

Advancing Biomedical Research

A Translational Research Platform — Hyderabad, India

INDIA PAVILION · BIO 2026

OUR PLATFORMS

● BIOMATERIALS

ECM-mimicking Peptide
PepSira · BioSira

● BIOFABRICATION

Organ-on-Chip & Microfluidics

● EXOSOMES

EVs & Diagnostics
ExoTIK · EVAR

● BIOINFORMATICS

AI-driven Discovery
EVAR · PepVAR

FLAGSHIP PRODUCTS



DAD Kit™
Dynamic Apoptosis
Detection



ExoTIK™
Exosome Total
Isolation Kit



BioSira™
Atelocollagen
Type I Bioink

CENTRE OF EXCELLENCE

Supported by the

GOVERNMENT OF TELANGANA

AWARDS & RECOGNITIONS

Top 5 Mahakumbh 2025 · Top 5 BioASIA 2025 · Winner Elevate IIT-Madras 2024
Winner IKMC 2024 Biopharma · IKP Rise 2024

OPEN FOR PARTNERSHIPS

Licensing · Co-Development · Distribution · Research Collaborations

www.biovaram.com

sales@biovaram.com · communications@biovaram.com · +91 91542 54190

Suite 19, ASPIRE-BioNEST, School of Life Sciences, University of Hyderabad, Hyderabad 500046, India

BioVaram is a brand of UR Advanced Therapeutics Pvt. Ltd.



Global CRO with a presence across 25+ countries, offering integrated end-to-end development solutions spanning preclinical research through late-phase clinical trials

Veeda Lifesciences is the full-service, Tech driven, Global CRO with a presence across 25+ countries, offering integrated end-to-end development solutions spanning preclinical research through late-phase clinical trials. We partner with pharmaceutical, biotechnology, and healthcare companies to accelerate the development of innovative therapies across a broad range of therapeutic areas.

Our expertise encompasses New Biological Entities (NBE), New Chemical Entities (NCE), biosimilars, and generics, supported by extensive experience in complex development programs and highly regulated markets. Through a combination of scientific excellence, operational agility, and regulatory insight, Veeda helps sponsors navigate critical development milestones efficiently and confidently.

With deep knowledge of regulatory

requirements across the United States, Europe, and other major global markets, we support our partners in:

- ④ Accelerating development timelines
- ④ Strengthening regulatory strategy and inspection readiness
- ④ Optimizing study design and operational execution
- ④ Delivering cost-efficient, high-quality outcomes

Our integrated capabilities across preclinical, clinical, bioanalytical, biometrics, pharmacovigilance, medical writing, and regulatory services enable seamless progression from discovery to approval. Backed by experienced scientific teams, advanced infrastructure, and a commitment to quality, Veeda serves as a trusted development partner for organizations seeking speed, reliability, and global execution excellence.



www.veedalifesciences.com



info@veedalifesciences.com



Accelerating Innovation Through Integrated Preclinical Research

Vipragen Biosciences Pvt. Ltd. is a leading **preclinical Contract Research Organization (CRO)** headquartered in **Mysuru**, delivering high-quality scientific research services to global pharmaceutical, biotechnology, medical device, and chemical industries.



CORE EXPERTISE

Vipragen provides end-to-end preclinical research services, including:

- Discovery & Exploratory Research
- Regulatory Toxicology Studies
- Genetic Toxicology
- Developmental & Reproductive Toxicology (DART)
- Safety Pharmacology
- Analytical & Bioanalytical Services
- Medical Device Safety Evaluation

INFRASTRUCTURE & QUALITY

Vipragen Biosciences operates a state-of-the-art research facility accredited with **OECD GLP, NABL, and AAALAC**, and adheres to **RRR (Replacement, Reduction, and Refinement) principles**, supported by a network of advanced allied laboratories. Equipped with **cutting-edge instrumentation** and **robust quality systems**, Vipragen delivers **high-quality, regulatory-compliant data** designed to support **global regulatory submissions**

INDUSTRIES WE CATER

Vipragen supports product development across diverse sectors:

- Pharmaceuticals & Biologics
- Vaccines & Biotechnology
- Medical Devices
- Nutraceuticals & Cosmetics
- Agrochemicals & Industrial Chemicals

INNOVATION FOCUS

Vipragen actively contributes to the advancement of New Approach Methodologies (NAMs) and alternative testing models to enhance predictive toxicology and improve research efficiency.

WHY VIPRAGEN BIOSCIENCES?

- Experienced multidisciplinary scientific team
- Global regulatory expertise
- Integrated research solutions
- Strong quality and compliance framework
- Trusted partner for global life-science innovators

CORPORATE OFFICE:

Centre for Cellular and Molecular Platforms (C-CAMP)
GKVK Campus, Bellary Road,
Bengaluru - 560 065, India

GLP TEST FACILITY:

Hootagalli
Industrial Area,
Mysuru - 570 018,
India

GLOBAL PRESENCE:

USA
Europe
Japan

✉ info@vipragen.com
bd@vipragen.com

www.vipragen.com



Yashraj Biotechnology Ltd. (YBL), a premier ISO-certified life sciences leader specializing in high-quality antigens and antibodies for the global In Vitro Diagnostics (IVD) industry and advanced drug discovery

Established in 1999 and headquartered in Navi Mumbai, Yashraj Biotechnology Ltd. (YBL) is a premier ISO-certified life sciences leader specializing in high-quality antigens and antibodies for the global In Vitro Diagnostics (IVD) industry and advanced drug discovery.

Operating from a 200,000 sq. ft. state-of-the-art facility, YBL leverages a unique hospital network to source diverse clinical samples, enabling the purification of native-state biomarkers that ensure superior diagnostic accuracy and batch-to-batch consistency.

Beyond diagnostics, the company's Integrated Drug Discovery & Development division utilizes in-house

iPSC technology to provide human-relevant Non-Animal Model (NAM) solutions, including CiPA-validated cardiomyocytes and disease-in-a-dish models. These innovations align with global regulatory shifts like the FDA Modernization Act, promoting ethical, high-throughput research.

With over 25 years of expertise and a sophisticated R&D team, YBL serves as a strategic partner to global biopharma companies, providing the innovative tools and consistent raw materials necessary to drive diagnostic excellence and improve patient outcomes worldwide.



www.yashraj.com



Info@Yashraj.com

FOCUS AREAS



Inputs for Streamlining Regulatory Process



Inputs for Accelerating BioEconomy through Advocacy



Industry Recommendations for the Union Budget for the Biotech Sector



Proposing Fiscal Incentives for Biotech Sector



Strengthening IPR System



Proactive Member Focus Initiatives



Catalysing Opportunities for Start-ups and SMEs



Proposals for Venture Capital Fund



Kindling & Fostering the Fire of Entrepreneurship



Encouraging the Biotech Sector through Investment



Facilitating Partnership through Industry, Academia & Start-up



Promoting more Incubators in Biotech Clusters



Working Closely with the State Government & Identify Potential Opportunities for Biotech Development



Promoting Entrepreneurship & Imparting Skill development for freshers in Biotech



Support Student Internship Programs & Facilitate Placement



Promoting Biotech among Budding Biotech Students through various Competitions



able | Pursuing
Infinite
Opportunities
Association of Biotechnology Led Enterprise